Search

The article highlights the participation of the European Association of Nuclear Medicine (EANM) Committee Molecular Imaging and Therapy at the 2007 Radiological Society of North America (RSNA) Inc. meeting in the U.S. EANM is steady dissiminating and fruitfully implementing its ideas in many counties of Eastern Europe. During the meeting, M. Schäfers and O. Schober presented two posters and handouts illustrating European activities in molecular imaging on behalf of the EANM.

Presents news briefs related to nuclear medicine as of March 2003. Organization of a symposium on radionuclides in Monterey, California, by the Czech Society of Nuclear Medicine; Overview of the 8th World Federation of Nuclear Medicine and Biology organized in Santiago, Chile; Summary of the third international conference on lymphatic mapping organized in Yokohama, Japan.

The author reflects on the study of nuclear medicine and its new procedures and materials. He relates that nuclear medicine is defined in the U.S. Accreditation Council for Graduate Medical Education (ACGME) program as a medical specialty which uses the tracer principle. The author mentions that the major procedure and materials incorporated in nuclear medicine include aerosol ventilation studies, myocardial perfusion imaging, and somatostatin analogues.

Reports various news developments related to nuclear medicine in the U.S. as of July 2004. Grant of Scientist of the Year Award to David M. Goldenberg by the Clinical Ligand Assay Society; Highlights of the Twelfth Congress of the European Society if Surgical Oncology held on April in Budapest, Hungary; Schedule of the Fourth International Sentinel Node Conference.

In the nuclear medicine laboratories of nuclear medicine clinics in European hospitals, quality assurance varies from non-existent to good manufacturing practice level. Thus at the business meeting of the Committee on Radiopharmacy of the EANM in Vienna in 2002, it was deemed of urgent interest to provide the nuclear medicine community in Europe with guidelines which would ensure a necessary and sufficient level of safety and efficacy in the production, reconstitution and handling of radiopharmaceuticals in hospitals, both for classical radiopharmaceuticals and for PET products. After discussions within the radiopharmacy and radiopharmaceutical chemistry community, including at the annual meeting of the Radiopharmacy Group of the German Society of Nuclear Medicine (DGN), the committee has adopted the strategy of starting to develop -Draft guidelines for radiopharmacy" for nuclear medicine laboratories and to adapt the -Preliminary draft regulations on current good manufacturing practices for PET drugs" of the U.S. Food and Drug Administration for European purposes.